JP2021518393A5 - - Google Patents

Info

Publication number
JP2021518393A5
JP2021518393A5 JP2020550650A JP2020550650A JP2021518393A5 JP 2021518393 A5 JP2021518393 A5 JP 2021518393A5 JP 2020550650 A JP2020550650 A JP 2020550650A JP 2020550650 A JP2020550650 A JP 2020550650A JP 2021518393 A5 JP2021518393 A5 JP 2021518393A5
Authority
JP
Japan
Prior art keywords
approximately
antibody
seq
concentration
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020550650A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518393A (ja
JP7217287B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/023528 external-priority patent/WO2019183448A1/en
Publication of JP2021518393A publication Critical patent/JP2021518393A/ja
Publication of JP2021518393A5 publication Critical patent/JP2021518393A5/ja
Application granted granted Critical
Publication of JP7217287B2 publication Critical patent/JP7217287B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020550650A 2018-03-23 2019-03-22 アミロイド症の処置および予防 Active JP7217287B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862647341P 2018-03-23 2018-03-23
US62/647,341 2018-03-23
PCT/US2019/023528 WO2019183448A1 (en) 2018-03-23 2019-03-22 Treatment and prophylaxis of amyloidosis

Publications (3)

Publication Number Publication Date
JP2021518393A JP2021518393A (ja) 2021-08-02
JP2021518393A5 true JP2021518393A5 (cg-RX-API-DMAC7.html) 2022-03-29
JP7217287B2 JP7217287B2 (ja) 2023-02-02

Family

ID=66041747

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020550650A Active JP7217287B2 (ja) 2018-03-23 2019-03-22 アミロイド症の処置および予防

Country Status (13)

Country Link
US (1) US20210017278A1 (cg-RX-API-DMAC7.html)
EP (1) EP3768311A1 (cg-RX-API-DMAC7.html)
JP (1) JP7217287B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200143400A (cg-RX-API-DMAC7.html)
CN (1) CN112040983A (cg-RX-API-DMAC7.html)
AU (2) AU2019240413A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020019172A2 (cg-RX-API-DMAC7.html)
CA (1) CA3095100A1 (cg-RX-API-DMAC7.html)
EA (1) EA202092264A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020009920A (cg-RX-API-DMAC7.html)
MY (1) MY203432A (cg-RX-API-DMAC7.html)
SG (1) SG11202009295YA (cg-RX-API-DMAC7.html)
WO (1) WO2019183448A1 (cg-RX-API-DMAC7.html)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2237803T3 (en) * 2007-12-28 2015-10-05 Prothena Biosciences Ltd Treatment and prophylaxis of amyloidosis
CN107233569B (zh) * 2011-10-25 2021-08-31 普罗西纳生物科学有限公司 抗体制剂和方法
ES2914781T3 (es) * 2016-06-30 2022-06-16 Prothena Biosciences Ltd Composiciones para el tratamiento de la amiloidosis

Similar Documents

Publication Publication Date Title
JP2025037879A (ja) 抗ｂｃｍａ重鎖のみ抗体
JP7352973B2 (ja) 二重特異性抗体及びその使用
JP7621939B2 (ja) ＲＧＭｃ選択的阻害剤およびその使用
JP2021526534A5 (cg-RX-API-DMAC7.html)
RU2019111722A (ru) Антитела против siglec-15 и способы их применения
JP2018529635A5 (cg-RX-API-DMAC7.html)
RU2015144105A (ru) Антитела к гепсидину и их применения
RU2016137110A (ru) Антитела к компоненту комплемента с5
JP2023542290A5 (cg-RX-API-DMAC7.html)
CN110799543A (zh) 肝细胞癌的免疫治疗
RU2018100824A (ru) Антитела, которые связываются с сортилином и подавляют связывание програнулина
CN110087683A (zh) 稳定水性抗c5抗体组合物
JP2021511387A5 (cg-RX-API-DMAC7.html)
JP2019519584A5 (cg-RX-API-DMAC7.html)
RU2019140933A (ru) Средства, пути применения и способы лечения
JP2020533965A5 (cg-RX-API-DMAC7.html)
JP2020527152A5 (cg-RX-API-DMAC7.html)
JP2024534602A5 (cg-RX-API-DMAC7.html)
WO2019076277A1 (zh) 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
JP2023537078A5 (cg-RX-API-DMAC7.html)
JP2022500382A5 (cg-RX-API-DMAC7.html)
JP2025502061A5 (cg-RX-API-DMAC7.html)
JP2020505350A5 (cg-RX-API-DMAC7.html)
CN115957321A (zh) 一种抗her2抗体在制备治疗癌症的药物中的用途
TW202321303A (zh) 抗pla2r自體抗體媒介膜性腎病變之治療